Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Navocaftor +/- Galicaftor in Cystic Fibrosis (F508del Homozygous)
NCT03969888Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Dec 2019
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, double-blind trial of navocaftor and galicaftor in cystic fibrosis (CF) (8 arms), sponsored by AbbVie Inc. Primary endpoint: Percent Predicted Forced Expiratory Volume in 1 Second at Day 29. Started Dec 2019; status: completed.
02
Drugs
navocaftorgalicaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT03969888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969888.